LOGIN  |  REGISTER

Latest Diagnostics & Research Stock News

Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27

CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on June 27, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Simon Morriss, CEO of...Read more


Radiopharm Receives Strategic Investment for up to A$18 million

June 20
Last Trade: 79.38 -2.10 -2.58

Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm Offer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19 June 2024 Option for Lantheus to invest a further A$7.5m within 6 months on the same terms Lantheus will also secure rights to two early preclinical assets in exchange for an A$3m upfront payment pursuant to a transfer and development...Read more


Applied DNA Sciences and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics

June 20
Last Trade: 0.46 -0.02 -3.61

Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand STONY BROOK, NY AND JUPITER, FL / ACCESSWIRE / June 20, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and Alphazyme LLC (Alphazyme), a...Read more


Critical Path and Centogene MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

June 20
Last Trade: 0.40 -0.01 -2.47

TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, are pleased to announce the signing of a Memorandum of Understanding (MOU) to advance drug development...Read more


Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People With Type 2 Diabetes

June 20
Last Trade: 115.68 -0.39 -0.34

Dexcom unveils more clinical data reaffirming the benefits of Dexcom CGM use among people with Type 2 diabetes than at any previous ADA conference. ADA conference presentations reiterate the advantages of Dexcom CGM use alongside incretin therapies such as GLP-1s.1,2 New Dexcom G7 automated insulin delivery integrations* further solidify the company’s undisputed leadership in CGM connectivity. Recently released Dexcom G7 app updates,...Read more


Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics

June 19
Last Trade: 252.64 4.08 1.64

WASHINGTON, June 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a leading global life sciences and diagnostics innovator, today announced that Julie Sawyer Montgomery will succeed Joakim Weidemanis as Executive Vice President, Diagnostics effective as of July 1, 2024. Mr. Weidemanis will support the transition over the next three months and will retire from Danaher on September 30, 2024 after 13...Read more


Telo Genomics Announces Its TeloViewSMM Test Is Accepted as Laboratory Developed Test by CAP

June 18
Last Trade: 0.19 -0.01 -5.13

Toronto, Ontario--(Newsfile Corp. - June 18, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications measuring genomic instability in oncology, is pleased to announce that the College of American Pathologists (CAP) has recently accepted Telo Genomics' submission to add Telo's test for...Read more


Prenetics Global Announces First Quarter 2024 Financial Results

June 18
Last Trade: 5.96 -0.13 -2.13

First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S. Consumer Healthcare Market Reaffirms 2024 Revenue Range of US$33 million to US$36 million LOS ANGELES, June 18, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the...Read more


Charles River Laboratories and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy

June 17
Last Trade: 210.39 0.75 0.36

Leveraging CGT CDMO expertise to support T-cell immunotherapy clinical trial WILMINGTON, Mass. / Jun 17, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP),...Read more


Labcorp Launches Global Trial Connect to Accelerate Clinical Trials

June 17
Last Trade: 205.91 -1.47 -0.71

Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows BURLINGTON, N.C. , June 17, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical...Read more


Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients

June 17
Last Trade: 107.85 0.65 0.61

Donor Quantity Score (DQS) technique is unique to Natera, improving detection of both acute cellular rejection and antibody-mediated rejection AUSTIN, Texas / Jun 17, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS), further enhancing Prospera’s ability to detect rejection in heart transplant...Read more


Co-Diagnostics Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

June 14
Last Trade: 1.46 0.01 0.70

The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY, June 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that...Read more


Qiagen’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs

June 13
Last Trade: 41.36 -0.53 -1.27

Venlo, the Netherlands, and Redwood City, California, June 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of a new version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), that brings significant performance and scalability enhancements tailored for high-throughput, next-generation sequencing (NGS) labs moving to larger test panels...Read more


Applied DNA Sciences Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health

June 13
Last Trade: 0.46 -0.02 -3.61

STONY BROOK, NY / ACCESSWIRE / June 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that the New York State Department of Health ("NYSDOH") approved the Company's TR8™ PGx ("TR8") pharmacogenomic (PGx) testing service. The Company is currently in discussions to provide large-scale testing to enterprise customers, healthcare networks, and...Read more


NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting

MALVERN, Pa., June 13, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today their participation at the 12th Annual Meeting of the Clinical TMS Society (CTMSS) in London, England from June 13th-15th. Six posters and one oral presentation will feature...Read more


Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update

June 13
Last Trade: 1.09 0.00 0.00

FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024. Third Quarter Highlights The Company's Life Science division's third-quarter revenue of $8.0 million improved year-over-year by 7%, marking four consecutive quarters of revenue growth compared to the prior year quarterly periods. Revenue for...Read more


Telo Genomics Presents Proprietary Artificial Intelligence Methodologies at ASCO 2024

June 12
Last Trade: 0.19 -0.01 -5.13

Toronto, Ontario--(Newsfile Corp. - June 12, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3D0A) ("Telo" or the "Company"), is pleased to announce that results of the development, validation and implementation of its machine learning and Artificial Intelligence (AI) modules, used in its TeloView myeloma diagnostic tests, were presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting that took place...Read more


IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites

June 12
Last Trade: 215.15 0.96 0.45

Bold initiative to boost the capacity of research sites enters Beta testing and piloting RESEARCH TRIANGLE PARK, N.C. / Jun 12, 2024 / Business Wire / IQVIA (NYSE:IQV) today announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site needs to perform across all of the clinical trials it is conducting. Clinical...Read more


Qiagen launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance

June 11
Last Trade: 41.36 -0.53 -1.27

Venlo, the Netherlands, June 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its digital PCR (dPCR) platform QIAcuity, significantly enhancing its offerings in the field of microbial research. The new assays are available on QIAGEN’s comprehensive research platform GeneGlobe and are designed to target a wide...Read more


Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

June 11
Last Trade: 24.25 0.45 1.89

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. A new sponsored testing program leveraging Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests (collectively...Read more


RadNet to Present at the Sidoti & Company 2024 Small Cap Conference on Wednesday, June 12th

LOS ANGELES, June 11, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Sidoti & Company 2024 Small Cap Conference on Wednesday, June 12th at 12:15 p.m....Read more


PacBio and International Research Consortium CoLoRS Announce Release of First-Ever HiFi Long-Read Variant Database

June 10
Last Trade: 1.53 -0.04 -2.41

Consortium Delivers Publicly Available Datasets that Enrich Detection of Rare and Novel Genetic Variants for Advances in Human Disease Research MENLO PARK, Calif., June 10, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, in collaboration with the international Consortium for Long-Read Sequencing (CoLoRS), today announced the launch of the first publicly...Read more


Quantum-Si Announces Presentation on the Use of Next-Generation Protein Sequencing™ to Detect Disease-Relevant Proteoforms at the Festival of Genomics and Biodata

June 10
Last Trade: 1.20 -0.11 -8.40

BRANFORD, Conn. / Jun 10, 2024 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a presentation by Gloria Sheynkman, Ph.D., Assistant Professor in the Department of Molecular Physiology and Biological Physics at the University of Virginia at the Festival of Genomics and Biodata conference being held in Boston on June 12-13, 2024. The...Read more


Surmodics Awarded Thrombectomy Products Agreement with Premier

June 10
Last Trade: 41.93 -0.02 -0.05

Access to Premier’s healthcare group purchasing organization (GPO) expected to expand national market reach for Surmodics endovascular thrombectomy solutions. EDEN PRAIRIE, Minn. / Jun 10, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective...Read more


RadNet to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

LOS ANGELES, June 07, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:40...Read more


Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor

June 6
Last Trade: 49.93 1.19 2.44

TB206-001 shown to be a high-affinity, cross-reactive humanized antibody antagonist of A2AR with in vivo tumor suppressing activity TB206-001 available for out-licensing SOUTH SAN FRANCISCO, Calif. / Jun 06, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the publication of a study...Read more


Olink Target 48 Immune Surveillance Panel – The Next Frontier in Immune Biomarker Profiling with Absolute Confidence

June 6
Last Trade: 25.55 0.04 0.16

UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research. More Confidence, More Insights, Less Sample Biomarker selection for Olink Target 48 Immune Surveillance...Read more


Izotropic Announces Non-Brokered Private Placement

June 6
Last Trade: 0.13 0.00 0.00

Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, announced today that it intends to complete a small non-brokered private placement financing (the "Offering") of up to 3,000,000 units of the Company, (each a "Unit") at a price of $0.10 per...Read more


Qiagen launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe

June 5
Last Trade: 41.36 -0.53 -1.27

Venlo, the Netherlands, June 05, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several other enhancements in its GeneGlobe Design and Analysis Hub, a comprehensive research platform that integrates pre-designed assays with a database of...Read more


Applied DNA Sciences Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea(TM) IVT Platform

June 5
Last Trade: 0.46 -0.02 -3.61

Patent covers the Composition of the Company's Proprietary Linea™ RNAP, a Core Technology Empowering the Linea™ IVT Platform Patent Application Also Currently Pending in Key International Markets STONY BROOK, NY / ACCESSWIRE / June 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, announced today that it received a Notice of Allowance from the United States...Read more


23andMe Launches New Genetic Report on Bipolar Disorder

June 5
Last Trade: 0.42 0.0047 1.13

SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition. Bipolar disorder is a mental health condition that can cause extreme and unusual shifts...Read more


Dexcom G7 Now Connects Directly to Apple Watch in the U.S.

June 5
Last Trade: 115.68 -0.39 -0.34

Diabetes management goes hands-free as Dexcom G7 now connects directly to Apple Watch* in the U.S., giving users confidence even when their iPhone isn’t with them† As the first and only CGM system that connects directly to Apple Watch,* Dexcom G7 gives users the freedom and convenience of real-time glucose readings on their wrist Direct to Apple Watch is now available to Dexcom G7 users in the United States, United Kingdom and Ireland,...Read more


Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost

June 4
Last Trade: 107.63 -0.62 -0.57

SAN DIEGO, June 4, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that it has completed integration of its latest chemistry, XLEAP-SBS™, into all reagents for its NextSeq™ 1000 and NextSeq 2000 next-generation sequencing (NGS) instruments.   "We are excited to deliver for our NextSeq 1000/2000 customers improved sequencing with faster run times,...Read more


Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer

June 4
Last Trade: 29.89 0.33 1.12

Upgraded gene panel on tissue genomic profiling test covers 498 biomarkers, including guideline-recommended genes Operational improvements streamline workflow and shorten time to results Upgraded test covered by Medicare for comprehensive genomic profiling of all advanced solid tumors PALO ALTO, Calif. / Jun 04, 2024 / Business Wire / Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch...Read more


IDEXX Laboratories Expands Test Menu for the Catalyst Platform to Support Veterinarians Globally in Diagnosing Pancreatitis

June 4
Last Trade: 493.35 -2.61 -0.53

The launch of the Catalyst® Pancreatic Lipase Test demonstrates IDEXX's Technology for Life strategy and will provide veterinarians with quantitative results at the point-of-care in less than 10 minutes  WESTBROOK, Maine, June 4, 2024 /CNW/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announces the launch of the Catalyst® Pancreatic Lipase Test, a single-slide solution for canine...Read more


ICON to Present at the Jefferies Global Healthcare Conference

DUBLIN / Jun 04, 2024 / Business Wire / ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 1:30pm ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under “Events”. About ICON plc ICON...Read more


Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

June 3
Last Trade: 24.25 0.45 1.89

SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test. RiskScore combines a...Read more


Nova Scotia Now Providing Coverage for Dexcom Continuous Glucose Monitoring Systems

June 3
Last Trade: 115.68 -0.39 -0.34

Nova Scotia becomes the latest province and territory to offer access to simple and easy-to-use diabetes management solutions, helping Canadians living with diabetes take control of their health BURNABY, British Columbia / Jun 03, 2024 / Business Wire / Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, today announced that residents of Nova Scotia living with...Read more


Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials

Data from study using Guardant360® blood test show Black patients with PIK3CA mutations in advanced breast cancer were less likely than White patients to be enrolled in clinical trials and receive targeted therapy Study is part of collaboration between Guardant Health and Multicenter Precision Medicine Academic Consortium (PMAC) using liquid biopsy to achieve equitable use of precision medicine therapies in patients with metastatic...Read more


Tempus AI Announces New Features to its Smart Physician Platform, Hub

Tempus, a leader in artificial intelligence and precision medicine, today announces a suite of new features in its physician platform, Hub. Trusted by thousands of oncologists and care teams, Hub is an AI-enabled platform that provides access to patient insights in a secure environment. Tempus is now unveiling a collection of new and enhanced features designed to make it easier for clinicians to access each of their patient’s...Read more


Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

June 3
Last Trade: 563.37 6.16 1.11

The Thermo Scientific™ Stellar™ mass spectrometer combines speed and sensitivity to advance precision medicine ANAHEIM, Calif. / Jun 03, 2024 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Stellar™ mass spectrometer (MS), a new solution that combines fast throughput, high sensitivity, and ease of use to allow researchers to advance their...Read more


Waters Sets New Standards for High Resolution Performance and Speed with Xevo MRT Mass Spectrometer

June 3
Last Trade: 288.94 -1.06 -0.37

News Summary: Waters Xevo™ MRT Mass Spectrometer employs next-generation multi-reflecting time-of-flight technology to deliver class-leading combination of high resolution and speed without compromising analytical performance.i Delivers up to 6x resolution at maximum speed and up to 2x mass accuracy of competitive systems,ii enabling scientists to process more samples in less time for large-cohort biomedical research and...Read more


Charles River Laboratories to Present at William Blair and Jefferies Conferences

June 3
Last Trade: 210.39 0.75 0.36

WILMINGTON, Mass. / Jun 03, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4th, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:00 a.m. ET. Management will present an overview of Charles River’s strategic focus, business...Read more


Fulgent Genetics Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer

EL MONTE, Calif. / Jun 03, 2024 / Business Wire / Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, was presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024 in...Read more


Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

June 3
Last Trade: 0.47 -0.09 -16.87

New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study represents the third consecutive confirmation of the consistently good performance of Mainz Biomed’s mRNA biomarkers to detect CRC and precancerous lesions BERKELEY, Calif. and MAINZ, Germany, June 03, 2024 (GLOBE...Read more


Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

AUSTIN, Texas / Jun 03, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 7:40 a.m. PT (10:40 a.m. ET). A live webcast may be accessed through the investor relations section of the Natera website at investor.natera.com. A replay of the event will be available...Read more


23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting

June 3
Last Trade: 0.42 0.0047 1.13

23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and achieves the prespecified targets for maximal pharmacology at 1400 mg dosed Q3W Tumor CD200 is emerging as a potential biomarker associated with 23ME-00610 monotherapy efficacy SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE...Read more


Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients

June 3
Last Trade: 14.13 0.16 1.15

Surveillance Monitoring with Both AlloSure Kidney and the AlloView AI-Enabled Risk Prediction Model Improves the Detection of All Types of Allograft Rejection AlloSure Kidney Detected Subclinical Rejection in Clinically Stable Patients and AlloSure Kidney dd-cfDNA Levels were Elevated Prior to Biopsy Proven Rejection in an Analysis of Patients Receiving Consecutive Biopsies AlloSure dd-cfDNA Levels Declined in Response to...Read more


Labcorp Announces New Strategic Service Offerings within Precision Oncology Portfolio

June 3
Last Trade: 205.91 -1.47 -0.71

Labcorp® Tissue Complete, a comprehensive genomic profiling service, now available in Geneva and Shanghai to support global clinical trials Company expands leadership in liquid biopsy comprehensive genomic profiling for solid tumors with the integration of OmniSeq® INSIGHT circulating tumor DNA BURLINGTON, N.C., June 3, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services,...Read more


RadNet to Present at the Jefferies 2024 Global Healthcare Conference on June 5, 2024

LOS ANGELES, June 03, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, will be presenting at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024 at 11:30 a.m. Eastern...Read more


Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology

June 3
Last Trade: 2.55 0.08 3.24

DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring (“CGM”) microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company’s stakeholders with key insights into the Company’s vision for...Read more


Qiagen expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care

June 3
Last Trade: 41.36 -0.53 -1.27

Germantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States. The launch comes after the recent clearance of the syndromic test for clinical use by the U.S. Food and Drug Administration (FDA) and marks a significant step forward in improving the accuracy and efficiency of...Read more


Avricore Health Corporate Update – Company Achieves Profitability

June 3
Last Trade: 0.17 0.00 0.00

VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) reports on results for the first three months of 2024, the first period of net profitability for the Company.   The Company realized a comprehensive income of $168,537 for the three months ended March 31, 2024 (2023 - loss $191,512) and a net increase in cash of $307,470, demonstrating the Company’s...Read more


Tempus AI Announces New Features to its Smart Physician Platform, Hub

Tempus, a leader in artificial intelligence and precision medicine, today announces a suite of new features in its physician platform, Hub. Trusted by thousands of oncologists and care teams, Hub is an AI-enabled platform that provides access to patient insights in a secure environment. Tempus is now unveiling a collection of new and enhanced features designed to make it easier for clinicians to access each of their patient’s...Read more


Sotera Health Announces Closing of $1.5 Billion Term Loan B and $750 Million Senior Secured Note Financings

May 30
Last Trade: 11.85 0.27 2.33

CLEVELAND, May 30, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced that its direct subsidiary has successfully closed a new senior secured Term Loan B facility in an aggregate principal amount of $1.51 billion (the “TLB”) as well...Read more


Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance

May 30
Last Trade: 21.01 -0.07 -0.33

Castle to present a second poster on its DecisionDx®-UM test sharing data from an ongoing prospective, multi-center study of patients with uveal melanoma (UM) led by the Collaborative Ocular Oncology Group (COOG2) FRIENDSWOOD, Texas / May 30, 2024 / Business Wire / Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will present new data related...Read more


Qiagen and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

May 30
Last Trade: 41.36 -0.53 -1.27

Venlo, the Netherlands, and Salt Lake City, Utah, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims to support research into personalized medicine in multiple solid tumor types, including...Read more


Spectral Medical Announces Closing of Approximately C$8.5 Million Convertible Notes Financing

May 30
Last Trade: 0.49 -0.01 -2.00

TORONTO, May 30, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (TSX:EDT) (the "Company" or "Spectral"), is pleased to confirm the closing of previously announced offering of 9% convertible notes of the Company at a price of US$1,000 per convertible note due on May 1, 2028 for gross proceeds of approximately C$8.5 million (the “Offering”). Paradigm Capital Inc. acted as the underwriter for the Offering. The net proceeds from the Offering...Read more


Telo Genomics Announces Publication of Results from Its Smoldering Myeloma Clinical Study in the American Journal of Hematology

May 30
Last Trade: 0.19 -0.01 -5.13

Toronto, Ontario--(Newsfile Corp. - May 30, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the "Company" or "Telo"), a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications in oncology, is thrilled to announce that the manuscript titled, "Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma" was accepted...Read more


Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening

Studies demonstrate benefits of liquid biopsy and real-world data in targeted therapy selection and therapeutic outcomes in advanced breast cancer Interim data from PICI’s RADIOHEAD study using Guardant Infinity™ platform show correlation between epigenomic biomarkers and patient response to immunotherapy treatment across more than 13 cancer types PALO ALTO, Calif. / May 30, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a...Read more


Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024

Includes new results from the ProActive study, reinforcing the utility of the Prospera™ Kidney test for ongoing surveillance of transplant rejection AUSTIN, Texas / May 30, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its Prospera donor-derived cfDNA (dd-cfDNA) test at the American Transplant Congress (ATC)...Read more


Researchers Use Olink Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis

May 30
Last Trade: 25.55 0.04 0.16

UPPSALA, Sweden, May 30, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today reported the publication of a landmark study using the Olink Explore platform to identify proteins in the blood that may provide a 7-year warning for various cancers. The findings, published in Nature Communications, illustrate the tremendous potential of proteomics to revolutionize cancer detection, allowing for intervention at much earlier...Read more


Bionano Genomics Announces Robust Presence at Upcoming Cytogenetics Conferences ESHG and ACC with 39 Scientific Presentations and Posters Highlighting the Utility of the Optical Genome Mapping Workflow

A record 31 scientific presentations and posters at the 2024 European Society for Human Genetics (ESHG) Annual Conference and 8 scientific presentations and posters at the 2024 American Cytogenomics Conference (ACC) will highlight the application of optical genome mapping (OGM) in genetic disorder, rare disease, and cancer research applications Bionano will host a sponsored session at ESHG featuring an overview of the Company’s OGM...Read more


AI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress

AI-Derived AlloView Results Correlate with Presence and Type of Biopsy Proven Kidney Rejection Longitudinal Monitoring with AlloSure Kidney Enables Earlier Identification of Graft Injury and Assessment of Rejection Treatment KOAR Data Show Kidney Biopsies Informed by AlloSure Detect More Acute Rejection than Biopsies Based on Traditional Indications BRISBANE, Calif. / May 30, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) –...Read more


Labcorp to Present Multiple Abstracts across Precision Oncology at the 2024 ASCO Annual Meeting

May 30
Last Trade: 205.91 -1.47 -0.71

Abstracts offer insights into precision oncology diagnostics for triple-negative breast cancer, liquid biopsy and machine learning for tumor profiling BURLINGTON, N.C., May 30, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will present several abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (May 31 – June 4,...Read more


Bayer and Burning Rock Biotech collaborate to increase patient access to precision cancer medicines

May 30
Last Trade: 6.78 -0.02 -0.29

GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This...Read more


Castle Biosciences: New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis...

May 29
Last Trade: 21.01 -0.07 -0.33

In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy (ART) had 50% higher metastasis-free survival (MFS) rates, on average, and slowed disease progression compared to Class 2B patients who did not receive ART Patients with Class 1 test results, predicted to have a lower risk of metastasis, did not see an improvement...Read more


Agilent Technologies Reports Second-Quarter Fiscal Year 2024 Financial Results

May 29
Last Trade: 132.54 -0.19 -0.14

Full-year outlook revised to reflect slower market recovery Announces plan to repurchase $0.75 billion of its common stock by end of fiscal year Board of directors authorizes new $2.0 billion share repurchase program Highlights Revenue of $1.57 billion, down 8.4% reported and 7.4% core(1) from the second quarter of 2023. GAAP net income of $308 million; earnings per share (EPS) of $1.05, up 3% from the second quarter of...Read more


Qiagen launches new library preparation kit, facilitating multiomic studies and advancing precision medicine

May 29
Last Trade: 41.36 -0.53 -1.27

Venlo, the Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QIAseq Multimodal DNA/RNA Lib Kit. The new kit enables seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment based on hybrid-capture from a single...Read more


Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO

May 29
Last Trade: 107.63 -0.62 -0.57

Studies presented represent key focus areas, including building evidence for clinical utility of comprehensive genomic profiling; overcoming market access barriers, and progressing the whole-genome approach for MRD SAN DIEGO, May 29, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of its latest research being presented at the American Society of...Read more


Dexcom Announces Upcoming Conference Presentation

May 29
Last Trade: 115.68 -0.39 -0.34

SAN DIEGO / May 29, 2024 / Business Wire / DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th. The live presentation is scheduled to begin at approximately 4:20 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom...Read more


Genetic Technologies Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer

May 29
Last Trade: 1.70 0.05 2.73

MELBOURNE, Australia, May 29, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has released its novel Comprehensive Risk Assessment test that covers 100% of women at risk of developing breast and ovarian cancer. The innovative test, available to all women above the age of 30,...Read more


VolitionRx to Present at Jefferies Global Healthcare Conference

HENDERSON, Nevada, May 29, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that Cameron Reynolds, President and Group Chief Executive Officer, will present and be available for one-to-one meetings at the Jefferies Global Healthcare Conference in New York City. Presentation Details:Date: Wednesday, June 5, 2024Time: 3.30 pm ET (Track 3) Cameron...Read more


23andMe: Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history

May 29
Last Trade: 0.42 0.0047 1.13

The LRRK2 variant is strongly associated with symptoms of Parkinson’s disease (PD) that are different from non-variant carriers with the disease The study revealed novel findings of genetic “hotspots” in people from Mexico, Cuba, Puerto Rico, and Brazil, where the founder variant has sprung up in other communities 23andMe has the largest LRRK2 G2019S research cohort, and launched the Parkinson’s Impact Project (PIP) in 2018 to better...Read more


Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million

May 29
Last Trade: 41.93 -0.02 -0.05

EDEN PRAIRIE, Minn. / May 29, 2024 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it has entered into a definitive agreement to be acquired by GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology. Under the terms of the agreement, affiliates of GTCR...Read more


Burning Rock Biotech Reports First Quarter 2024 Financial Results

May 29
Last Trade: 6.78 -0.02 -0.29

GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the...Read more


Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers

May 28
Last Trade: 1.89 -0.03 -1.56

SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSAXT system from Carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. This instrument will enable Standard BioTools™ to further validate its SomaScan® Platform by measuring the kinetic properties of SOMAmer®...Read more


NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management

FT. MYERS, Fla. / May 28, 2024 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS® Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31–June 4 (booth #31093). “With cancer cases on the rise, we’ve seen tremendous growth in FDA-approved targeted therapies and immunotherapies,...Read more


Revvity to Present at Goldman Sachs Global Healthcare Conference

May 28
Last Trade: 108.03 0.53 0.49

WALTHAM, Mass. / May 28, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) will present at the 45th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. ET in Miami, FL. Prahlad Singh, president and chief executive officer, will provide an update on the Company and its strategic priorities. To register, click here. A live audio webcast will be available on the Events section of the Company’s website at...Read more


Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

May 28
Last Trade: 0.47 -0.09 -16.87

Key Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous Lesions Poster presentation showing new data on 690 subjects including previously unexamined and unreported samples from the pooled ColoFuture and eAArly DETECT studies utilizing the mRNA biomarkers, FIT test, and a proprietary AI Algorithm BERKELEY, Calif. and MAINZ, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a...Read more


Lantheus to Present at the William Blair 44th Annual Growth Stock Conference

May 28
Last Trade: 79.38 -2.10 -2.58

BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Paul Blanchfield, President, will present at the William Blair 44th Annual Growth Stock Conference at 2:40 p.m. CT on Tuesday, June 4. To access a live webcast of the...Read more


Bionano Genomics Announces Private Placement of Senior Secured Notes in Debt Restructuring that Improves Balance Sheet

May 28
Last Trade: 0.77 -0.04 -4.56

SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics Inc. (“Bionano” or the “Company”) (NASDAQ: BNGO) today announced that it has completed a private placement of senior secured convertible debentures due May 24, 2026. The Company received gross proceeds of $18.0 million in connection with the placement, which will allow the Company to completely retire the convertible debt financing previously entered into first in October 2023,...Read more


Fulgent Genetics Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting

EL MONTE, Calif. / May 24, 2024 / Business Wire / Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024 in...Read more


Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®

Data to be presented expands the body of evidence around the predictive and prognostic value of the Oncotype DX® test in all racial and ethnic groups New data showcase Exact Sciences’ commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients MADISON, Wis. / May 24, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and...Read more


Guardant Health: FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

May 23
Last Trade: 29.89 0.33 1.12

The advisory committee offers valuable non-binding recommendations for the FDA Blood test offers a convenient non-invasive screening option that overcomes barriers associated with current non-invasive screening tests Shield remains on track to become the first FDA-approved blood test that meets performance requirements for Medicare coverage1 PALO ALTO, Calif. / May 23, 2024 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a...Read more


Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the company’s Precise™ MRD Test, MyChoice® CDx HRD Companion...Read more


Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference

AUSTIN, Texas / May 23, 2024 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of Natera’s management will present at the 2024 Leerink Partners Healthcare Crossroads Conference on Thursday, May 30, 2024 at 8:40 a.m. PT (11:40 a.m. ET). A live webcast may be accessed through the investor relations section of the Natera website at investor.natera.com. A replay of...Read more


23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

May 23
Last Trade: 0.42 0.0047 1.13

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments On March 28, 2024 the Board of Directors of 23andMe formed a Special Committee comprised of independent directors to review...Read more


Neuronetics to Present at the William Blair 44th Annual Growth Stock Conference

MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Thursday, June 6, 2024. The Company is scheduled to present at 10:00am...Read more


Twist Bioscience to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. / May 23, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that its executives will present and participate in fireside chats at the following upcoming investor conferences: Patrick Finn, Ph.D., president and COO, will participate in a fireside chat at the...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB